Clinical predictors of molecular diagnosis in early-onset epilepsy: A phenotype-informed approach
DOI:
https://doi.org/10.3889/aph.2026.6876Keywords:
early-onset epilepsy, genetic testing, molecular diagnosis, clinical predictors, developmental delay, magnetic resonance imagingAbstract
Genetic testing is increasingly central to the etiologic evaluation of early-onset epilepsy, yet the probability of a molecular diagnosis varies substantially according to clinical phenotype. We aimed to identify routinely available clinical features associated with a definitive molecular diagnosis and to determine which retain independent predictive value. Material and methods: This study included 141 patients with seizure onset by 60 months of age and completed clinical genetic testing. Only findings sufficient to explain the clinical phenotype were classified as definitive molecular diagnoses. Candidate variables included pre-seizure development, family history, epilepsy-related features, neurologic/motor phenotype, syndromic/dysmorphic features, systemic manifestations, and brain MRI findings. Univariable associations were examined first, followed by a prespecified multivariable logistic regression model. Results: A definitive molecular diagnosis was established in 74/141 patients (52.5%). On univariable analysis, drug-resistant epilepsy, developmental regression, abnormal neurologic/motor phenotype, syndromic/dysmorphic features, systemic manifestations, and abnormal MRI were associated with higher diagnostic yield. Abnormal development before seizure onset showed the strongest association (OR 6.15, 95% CI 2.85–13.27). In the prespecified multivariable model, abnormal pre-seizure development (aOR 5.46, 95% CI 2.27–13.13), positive family history (aOR 4.14, 95% CI 1.64–10.45), and abnormal MRI (aOR 3.03, 95% CI 1.13–8.13) remained independently associated with a definitive molecular diagnosis, whereas syndromic/dysmorphic features did not. The model showed good discrimination (AUC 0.790; bootstrap 95% CI 0.726–0.877; cross-validated mean AUC 0.772). Diagnostic yield increased from 6.3% in patients with none of the three independent predictors to 79.2% in those with at least two. Conclusions: Abnormal development preceding seizure onset, positive family history, and abnormal brain MRI independently increased the probability of a definitive molecular diagnosis in early-onset epilepsy. These readily available clinical features may help prioritize genetic testing when access is limited, while their absence should not be used to exclude patients from molecular evaluation.
Downloads
References
1. Krey I, Platzer K, Esterhuizen A, et al. Current practice in diagnostic genetic testing of the epilepsies. Epileptic Disord Int Epilepsy J Videotape. 2022;24(5):765-786. doi:10.1684/epd.2022.1448
2. Smith L, Malinowski J, Ceulemans S, et al. Genetic testing and counseling for the unexplained epilepsies: An evidence-based practice guideline of the National Society of Genetic Counselors. J Genet Couns. 2023;32(2):266-280. doi:10.1002/jgc4.1646
3. Chowdhury SR, Whitney R, RamachandranNair R, Bijarnia Mahay S, Sharma S. Genetic Testing in Pediatric Epilepsy: Tools, Tips, and Navigating the Traps. Pediatr Neurol. 2024;157:42-49. doi:10.1016/j.pediatrneurol.2024.05.008
4. Sheidley BR, Malinowski J, Bergner AL, et al. Genetic testing for the epilepsies: A systematic review. Epilepsia. 2022;63(2):375-387. doi:10.1111/epi.17141
5. Stefanski A, Calle-López Y, Leu C, Pérez-Palma E, Pestana-Knight E, Lal D. Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability: A systematic review and meta-analysis. Epilepsia. 2021;62(1):143-151. doi:10.1111/epi.16755
6. Burk KC, Kaneko M, Quindipan C, et al. Diagnostic Yield of Epilepsy-Genes Sequencing and Chromosomal Microarray in Pediatric Epilepsy. Pediatr Neurol. 2024;150:50-56. doi:10.1016/j.pediatrneurol.2023.10.014
7. Henry OJ, Ygberg S, Barbaro M, et al. Clinical whole genome sequencing in pediatric epilepsy: Genetic and phenotypic spectrum of 733 individuals. Epilepsia. 2025;66(8):2966-2979. doi:10.1111/epi.18403
8. Wu F, Ji X, Cheng P, et al. Diagnostic Genetic Findings From Exome Sequencing in a Cohort of 1,109 Children With Epilepsy. Neurol Genet. 2026;12(3):e200387. doi:10.1212/NXG.0000000000200387
9. Galer PD, Parthasarathy S, Xian J, et al. Clinical signatures of genetic epilepsies precede diagnosis in electronic medical records of 32,000 individuals. Genet Med. 2024;26(11):101211. doi:10.1016/j.gim.2024.101211
10. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077. doi:10.1111/j.1528-1167.2009.02397.x
11. Chang YM, Huang YT, Lai PC. Genetic testing for diagnosing neurodevelopmental disorders and epilepsy: a systematic review and meta-analysis. Syst Rev. 2025;14(1):155. doi:10.1186/s13643-025-02896-y
12. Lee S, Seo GH, Kim SY, et al. Clinical utility of genome sequencing in rare diseases: lessons from a single-center study of 1,452 Korean families. NPJ Genomic Med. 2025;11(1):2. doi:10.1038/s41525-025-00538-9
13. Coryell J, Gaillard WD, Shellhaas RA, et al. Neuroimaging of Early Life Epilepsy. Pediatrics. 2018;142(3):e20180672. doi:10.1542/peds.2018-0672
14. Brock DC, Abbott M, Reed L, et al. Epilepsy panels in clinical practice: Yield, variants of uncertain significance, and treatment implications. Epilepsy Res. 2023;193:107167. doi:10.1016/j.eplepsyres.2023.107167
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ljelja Muaremoska- Kanzoska, Aspazija Sofijanova, Filip Duma, Todor Arsov

This work is licensed under a Creative Commons Attribution 4.0 International License.
All wrights are reserved.


